Amylyx Pharmaceuticals In...

3.98
0.16 (4.19%)
At close: Apr 17, 2025, 3:59 PM
3.98
0.00%
After-hours: Apr 17, 2025, 04:07 PM EDT

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.

It is also developing AMX0035 for other neurodegenerative diseases.

The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc. logo
Country United States
IPO Date Jan 7, 2022
Industry Biotechnology
Sector Healthcare
Employees 123
CEO Joshua B. Cohen

Contact Details

Address:
43 Thorndike Street
Cambridge, Massachusetts
United States
Website https://amylyx.com

Stock Details

Ticker Symbol AMLX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001658551
CUSIP Number 03237H101
ISIN Number US03237H1014
Employer ID 46-4600503
SIC Code 2834

Key Executives

Name Position
Joshua B. Cohen Co-Founder, Co-Chief Executive Officer & Director
Justin B. Klee Co-Founder, Co-Chief Executive Officer & Director
Gina M. Mazzariello J.D. Chief Legal Officer & General Counsel
James M. Frates M.B.A. Chief Financial Officer
Dr. Camille L. Bedrosian M.D. Chief Medical Officer
Dr. Machelle Manuel Ph.D. Vice President & Head of Global Medical Affairs
Linda A. Arsenault Chief Human Resources Officer
Lindsey Allen Head of Investor Relations & Communications
Tammy Sarnelli Global Head of Regulatory Affairs
Tom Holmes Chief Technical Operations Officer

Latest SEC Filings

Date Type Title
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Apr 02, 2025 4 Filing
Mar 24, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing